Category: All our news

All our news

ITCC-P4, first company in the world to offer preclinical drug tests for children with cancer

All our news

XenTech will attend AACR Annual Meeting in Orlando (Apr. 14-19 2023)

Philippe, Olivier and Delphine cordially invite you to stop by our Booth#618 to discuss our solid tumor PDX collection to bring your innovative research projects a step further !

Discover

All our news

XenTech will attend the World ADC London (Mar.- 13-16th)

Philippe and Olivier cordially invite you to stop by our Booth#12 to discuss our long experience in testing ADCs in our solid tumor PDX collection !

Discover

All our news

XenTech will attend the DDR inhibitors Summit 2023 (Boston, Jan. 24-26)

Our Head of R&D Oliver Déas will be delighted to discuss with you as he’ll be attending in person.

Discover

All our news

XenTech exhibits at EACR 2022 (Seville, Jun. 20-23 2022)

We’ll be exhibiting at EACR in Seville, stop by booth #50 !

Discover

Publications

Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification

Discover

Publications

Targeting genome integrity dysfunctions impedes metastatic potency in non-small-cell lung cancer circulating tumor cellderived eXplants

CTC-derived eXplants (CDX) offer systems for mechanistic investigation of CTC metastatic potency and may provide rationale for biology-driven therapeutics.

Discover

All our news

XenTech exhibits at AACR Annual Meeting (New Orleans, Apr.8-13 2022)

We’ll be exhibiting at AACR New Orleans from Apr.8th 2022, stop by our booth to chat with us (at last!)

Discover

Publications

STING protects breast cancer cells from intrinsic and genotoxic-induced DNA instability via a non-canonical, cell-autonomous pathway – Oncogene, Oct.8 2021

Discover

Publications

Paediatric Liver Cancer

A preclinical platform of mouse-transplanted human pediatric liver tumors to evaluate the efficacy of conventional and innovative anticancer therapy

Discover